Ribomic Inc. (4591.T)
JPY 95.0
(-2.06%)
JPY 95.0
(-2.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 155.8 Million JPY | -21.82% |
| 2022 | 199.3 Million JPY | -23.5% |
| 2021 | 260.53 Million JPY | 122.75% |
| 2020 | 116.96 Million JPY | 32.91% |
| 2019 | 88 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 154 Million JPY | -1.16% |
| 2023 Q4 | 155.8 Million JPY | -22.57% |
| 2023 Q3 | 201.23 Million JPY | 38.89% |
| 2023 Q2 | 144.88 Million JPY | -26.56% |
| 2023 Q1 | 197.27 Million JPY | -1.02% |
| 2023 FY | 155.8 Million JPY | -21.82% |
| 2022 Q3 | 336.54 Million JPY | 55.73% |
| 2022 Q2 | 216.1 Million JPY | 0.0% |
| 2022 Q4 | 199.3 Million JPY | -40.78% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 95.201% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -145.713% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.409% |
| Linical Co., Ltd. | 10.3 Billion JPY | 98.488% |
| Trans Genic Inc. | 3.81 Billion JPY | 95.913% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 73.601% |
| Soiken Holdings Inc. | 697.02 Million JPY | 77.647% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 94.842% |
| AnGes, Inc. | 2.78 Billion JPY | 94.414% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 69.664% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.828% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 55.895% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 90.556% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 67.014% |
| CanBas Co., Ltd. | 91.98 Million JPY | -69.38% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 85.753% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 80.76% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 73.758% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 96.337% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.465% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 72.496% |
| SanBio Company Limited | 2.25 Billion JPY | 93.09% |
| Healios K.K. | 11.28 Billion JPY | 98.619% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 37.991% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 57.775% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 35.482% |
| StemRIM | 187 Million JPY | 16.68% |
| CellSource Co., Ltd. | 677.73 Million JPY | 77.01% |
| FunPep Company Limited | 189.32 Million JPY | 17.702% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 73.899% |
| Stella Pharma Corporation | 1.44 Billion JPY | 89.207% |
| TMS Co., Ltd. | 97.68 Million JPY | -59.495% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -70.294% |
| Cuorips Inc. | 200.96 Million JPY | 22.468% |
| K Pharma,Inc. | 209.13 Million JPY | 25.498% |
| Takara Bio Inc. | 11.42 Billion JPY | 98.636% |
| ReproCELL Incorporated | 741.03 Million JPY | 78.974% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 83.022% |
| StemCell Institute Inc. | 3.85 Billion JPY | 95.953% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 82.849% |
| CellSeed Inc. | 301.04 Million JPY | 48.244% |